🎗️Лента новостей
Онкология
Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer
A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies.
🎗️
Онкология
Research Spotlight: Decoding NF1 Tumor Development - New Insights, New Treatment Possibilities
Research Spotlight: Decoding NF1 Tumor Development - New Insights, New Treatment Possibilities UVA Health
Онкология
Ruben Mesa: Advocate Health Comes Together in Pink to Support Cancer Research
Ruben Mesa: Advocate Health Comes Together in Pink to Support Cancer Research Oncodaily
Онкология
Sylvester Cancer Tip Sheet for Sept. and Oct., 2026 | Newswise
Sylvester Cancer Tip Sheet for Sept. and Oct., 2026 | Newswise Newswise
Онкология
FDA approves Tukysa combination for HER2-positive breast cancer
The FDA has approved tucatinib plus trastuzumab and pertuzumab as front-line maintenance therapy for adults with unresectable, locally advanced or metastatic HER2-positive breast cancer following induction treatment. Tucatinib (Tukysa, Seagen), an oral tyrosine kinase inhibitor, had previously been approved in 2020 as…
Онкология
В ТПУ завершили разработку модели для прогнозирования осложнений лучевой терапии при раке простаты
В ТПУ завершили разработку модели для прогнозирования осложнений лучевой терапии при раке простаты Vademec.ru
Онкология
Tashy’s Story Shows Why Research Matters for Every Child Diagnosed With Cancer - Children's Cancer Institute
Tashy’s Story Shows Why Research Matters for Every Child Diagnosed With Cancer - Children's Cancer Institute Oncodaily
🎗️
Онкология
Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”
Anthony Letai reflects on Year One as NCI Director: “The NCI is in business” The Cancer Letter
Онкология
Joanna Metzner-Sadurski: Honored to Be Part of a 25-Year Journey in Rural Cancer Research
Joanna Metzner-Sadurski: Honored to Be Part of a 25-Year Journey in Rural Cancer Research Oncodaily
Онкология
Montefiore joins national study testing early-stage breast cancer treatment without surgery
Montefiore joins national study testing early-stage breast cancer treatment without surgery Bronx Times
Онкология
Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival | Newswise
Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival | Newswise Newswise
Онкология
10 Bladder and Urothelial Cancer Trials to Watch at ESMO 2026
10 Bladder and Urothelial Cancer Trials to Watch at ESMO 2026 Oncodaily
Онкология
Oregon Surgical Wellness adds breast surgical oncologist Sara B. Cartwright to team
Oregon Surgical Wellness adds breast surgical oncologist Sara B. Cartwright to team KMTR